Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Divi's LaboratoriesNSE:DIVISLAB -0.77%93 3-Year EBITDA Growth Rate is 12.60% as of Mar. 2026, which is 0% above its 10-year median of 12.55. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 93/100 and a GF Value™ of ₹6,775.95 (Fairly Valued). The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Divi's Laboratories ranks better than 58.3% on this metric.
During the past 12 months, Divi's Laboratories's average EBITDA Per Share Growth Rate was 16.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Divi's Laboratories was 61.00% per year. The lowest was -62.30% per year. And the median was 12.55% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Divi's Laboratories 3-Year EBITDA Growth Rate Related Terms
NSE:DIVISLAB vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Divi's Laboratories 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Divi's Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.60% mean?
Divi's Laboratories (NSE:DIVISLAB) has a 3-Year EBITDA Growth Rate of 12.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Divi's Laboratories and its competitors. This is near median its historical median of 12.55. According to the industry distribution chart, Divi's Laboratories ranks #339 out of 813 companies in the Drug Manufacturers industry, placing it in the top 41.7%.
Is Divi's Laboratories' 3-Year EBITDA Growth Rate too high?
Divi's Laboratories' current 3-Year EBITDA Growth Rate of 12.60% is near median its 10-year median of 12.55. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Divi's Laboratories' value of 12.60% is 43.2% above this industry median. Based on the distribution chart, Divi's Laboratories ranks #339 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Divi's Laboratories has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Divi's Laboratories ranks #339 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Divi's Laboratories in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Divi's Laboratories' value of 12.60% is 43.2% above this benchmark. While the company's 10-year median is 12.55 vs. the industry median of 8.80, Divi's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Divi's Laboratories's current 3-Year EBITDA Growth Rate of 12.60% is 43.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Divi's Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Divi's Laboratories's current 3-Year EBITDA Growth Rate is 12.60%, which is near median its own 10-year median of 12.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,775.95, compared to a current price of ₹7,248.50 — trading 7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 12.60%, which is near median its 10-year median of 12.55 and 43.2% above the Drug Manufacturers industry median of 8.80. Divi's Laboratories' overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current 3-Year EBITDA Growth Rate is 12.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued.
The current stock price of ₹7,248.50 is trading 7% above its estimated GF Value™ of ₹6,775.95.
GuruFocus considers Divi's Laboratories to be Fairly Valued.
Key valuation signals for NSE:DIVISLAB:
3-Year EBITDA Growth Rate: 12.60% (near median its 10-year median of 12.55)
GF Value™: ₹6,775.95 vs. price of ₹7,248.50 (7% above fair value)
Industry Position: 43.2% above the Drug Manufacturers median (#339 of 813)
No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
93GF Score
Get the complete analysis for NSE:DIVISLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DIVISLAB has been successfully added to your 
